Design, synthesis and study of small molecules with both AR degradation and AKR1C3 inhibitory activities

被引：0
|
作者：
Xing, Enming [1 ]
Kong, Xiaotian [1 ]
Lou, Wei [2 ]
Shi, Ruihua [1 ]
Cheng, Xiaolin [1 ]
Gao, Allen C. [2 ]
Li, Pui Kai [1 ]
机构：
[1] Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA
[2] Univ Calif Davis, Davis, CA 95616 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5681
引用
收藏
页数：2
相关论文
共 50 条
  • [31] REGULATION OF INTRATUMORAL ANDROGEN SYNTHESIS IN PROSTATE CANCER BY THE DAB2IP/AKR1C3 SIGNALING AXIS
    Wu, Kaijie
    Wang, Bin
    Zhou, Jiancheng
    Hsieh, Jer-Tsong
    He, Dalin
    JOURNAL OF UROLOGY, 2015, 193 (04): : E819 - E819
  • [32] Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma
    Miller, Valerie L.
    Lin, Hsueh-Kung
    Murugan, Paari
    Fan, Michael
    Penning, Trevor M.
    Brame, Lacy S.
    Yang, Qing
    Fung, Kar-Ming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (04): : 278 - 289
  • [33] AKR1C3 PROMOTES AR-V7 PROTEIN STABILIZATION AND CONFERS ANTI-ANDROGEN RESISTANCE IN ADVANCED PROSTATE CANCER
    Liu, Chengfei
    Yang, Joy C.
    Lou, Wei
    Liu, Liangren
    Evans, Christopher P.
    Gao, Allen C.
    JOURNAL OF UROLOGY, 2019, 201 (04): : E318 - E318
  • [34] Network Pharmacological Study of the Active Ingredient of Panax Notoginseng Saponins for the Treatment of Lung Cancer by Inhibiting AKR1C3
    Wei, Yue-Zi
    Yang, Mei-Zhu
    Yuan, Wei
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (09) : 1546 - 1554
  • [35] Radiotherapy Resistance in Prostate Cancer Cells: AKR1C3 Inhibition of Ubiquitinated Degradation of Nrf2 through Interaction with KEAP1
    Lyu, F.
    Gao, X.
    Shang, S.
    Li, S.
    Ren, X.
    Chen, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E248 - E248
  • [36] Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis
    Fonseca-Benitez, Victoria
    Acosta-Guzman, Paola
    Sanchez, Juan Esteban
    Alarcon, Zaira
    Jimenez, Ronald Andres
    Guevara-Pulido, James
    MOLECULES, 2024, 29 (08):
  • [37] DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling
    Gu, Yanan
    Wu, Shiqi
    Chong, Yue
    Guan, Bing
    Li, Lei
    He, Dalin
    Wang, Xinyang
    Wang, Bin
    Wu, Kaijie
    CELLULAR SIGNALLING, 2022, 95
  • [38] AKR1C3 promotes progression and mediates therapeutic resistance by inducing epithelial-mesenchymal transition and angiogenesis in small cell lung cancer
    Liu, Wenting
    Li, Guoli
    Huang, Dingzhi
    Qin, Tingting
    TRANSLATIONAL ONCOLOGY, 2024, 47
  • [39] Type 2 3a/Type 5 17β-HSD (AKR1C3) Is a Negative Regulator of Breast Cancer Proliferation: An Immunohistochemical and In Vitro Study
    Murugan, P.
    Lin, H-K
    Wu, W.
    Miller, V.
    Yang, Q.
    Fung, K-M
    MODERN PATHOLOGY, 2012, 25 : 55A - 55A
  • [40] Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer
    Zhao, Jinge
    Ning, Shu
    Lou, Wei
    Yang, Joy C.
    Armstrong, Cameron M.
    Lombard, Alan P.
    D'Abronzo, Leandro S.
    Evans, Christopher P.
    Gao, Allen C.
    Liu, Chengfei
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (08) : 1708 - 1718
12345